Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Syphilis kits go under MHRA's (Medicines and Healthcare products Regulatory Agency) evaluation spotlight

This article was originally published in Clinica

Executive Summary

Ten syphilis EIAs feature in the second bacteriology kit evaluation report published this year by the Device Evaluation Service (DES) of the UK's Medicines and Healthcare products Regulatory Agency (MHRA). These assays are: Abbott Murex ICE Syphilis; Biokit Bioelisa Syphilis 3.0; biomerieux Trepanostika TP Recombinant; Bio-Rad Syphilis Total; Dade Behring Enzygnost Syphilis; Diesse Enzywell Syphilis; Microgen Bioproducts Mercia Syphilis; Newmarket Laboratories Syphilis EIA II; Omega Pathozyme Syphilis Competition; and Trinity Biotech Captia Syphilis. The report provides a description of the assays, a technical appraisal and details of specificity and sensitivity.

You may also be interested in...

AHPA Members Report Problems In Raw Material, Other Supplies In Pandemic Survey For USDA

Trade group also compiled website with information and resources to help members "stay up to date and take any necessary steps to mitigate the risks associated with COVID-19." Its members also got a chance to describe potential supply chain disruptions in survey for USDA.

COVID-19 Partnerships Without Formal Contracts Pose Risks, From Potential Liability To IP Issues

Companies are racing to co-develop coronavirus treatments before finalizing deal teams. These team-ups raise questions about what happens after the pandemic subsides.

‘Astonishing Results’ Or ‘Outrageous’ Claims? Peter Thomas Roth Fighting Bicoastal Class Actions

Plaintiffs against the prestige, “clinical” skin-care company are targeting anti-aging claims on its Rose Stem Cell Bio-Repair line and statements about hyaluronic acid’s ultra-moisturizing capabilities, used to market its Water Drench range. PTR faces false advertising class actions in California and New York federal courts, and the former case appears to be headed for trial.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts